Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7194-7204

  Ali, Sumia ^a   King, Gwendalyn D ^b   Curtin, James F ^b   Candolfi, Marianela ^b   Xiong, Weidong ^b   Liu, Chunyan ^b   Puntel, Mariana ^b   Cheng, Queng ^d   Prieto, Jesus ^d   Ribas, Antoni ^c   Kupiec Weglinski, Jerzy ^c   Van Rooijen, Nico ^e   Lassmann, Hans ^f   Lowenstein, Pedro R ^a,b   Castro, Maria G ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NAVARRA   (Spain)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CYCLOSPORIN; FLT3 LIGAND; HERPES SIMPLEX VIRUS 1 THYMIDINE KINASE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GLIOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PYRAMIDAL TRACT; RAT; SURVIVAL TIME; VIRAL GENE THERAPY;

ADENOVIRUSES, HUMAN; ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNITY; BRAIN; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYCLOSPORINE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; RATS; RATS, INBRED LEW; SPINAL CORD; THYMIDINE KINASE;

EID: 23844482747     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3434     Document Type: Article

References (61)

1. Counsell CE, Grant R. Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol 1998;37:241-50.
2. Pobereskin LH, Chadduck JB. Incidence of brain tumours in two English counties: a population based study. J Neurol Neurosurg Psychiatry 2000;69:464-71.
3. Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003;98:71-108.
4. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus I thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5:1256-63.
5. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 2004;10:1071-84.
6. Fulci G, Chiocca EA. Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front Biosci 2003;8:e346-60.
7. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998;9:2595-604.
8. Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H, Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther 2005;12:600-7.
9. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-205.
10. Marken JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase 1 trial. Gene Ther 2000;7:867-74.
11. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
12. Wilkinson GW, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 1992;20:2233-9.
13. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000;97:7482-7.
14. Thomas WS, Neal-Beliveau BS, Joyce JN. There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum. Brain Res Dev Brain Res 1998;111:99-106.
15. Godiska R, Chantry D, Raport CJ, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997;185:1595-604.
16. Lasarte JJ, Corrales FJ, Casares N, et al. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol 1999;162:5270-7.
17. Sun Y, Peng D, Lecanda J, et al. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 2000;7:1467-6.
18. Cowsill C, Southgate TD, Morrissey G, et al. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Ther 2000;7:679-85.
19. Shering AF, Bain D, Stewart K, et al. Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J Gen Virol 1997;78:445-59.
20. Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med 1999;5:955-7.
21. Dion LD, Fang J, Garver RI Jr. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods 1996;56:99-107.
22. Gotten M, Baker A, Saltik M, Wagner E, Buschle M. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther 1994;1:239-46.
23. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
24. Izquierdo M, Martin V, de Felipe P, et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996;3:491-5.
25. Jia WW, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 1994;86:1209-15.
26. Moriuchi S, Wolfe D, Tamura M, et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 2002;9:584-91.
27. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61:8743-50.
28. Tyynela K, Sandmair AM, Turunen M, et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther 2002;9:917-24.
29. Fischer HG, Bonifas U, Reichmann G. Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J Immunol 2000;164:4826-34.
30. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001;166:2717-26.
31. McMenamin PG. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in whole-mount preparations. J Comp Neurol 1999;405:553-62.
32. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000;157:1991-2002.
33. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β 2. J Immunol 1989;143:3222-9.
34. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
35. Zou GM, Tam YK. Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw 2002;13:186-99.
36. Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003;987:180-7.
37. Puccetti P, Belladonna ML, Grohmann U. Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. Crit Rev Immunol 2002;22:373-90.
38. Guillot C, Coathalem H, Chetritt J, et al. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. J Immunol 2001;166:5225-35.
39. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-61.
40. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.
41. Gitlitz BJ, Belldegrun AS, Zisman A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 2003;26:412-9.
42. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45-52.
43. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000;86:385-92.
44. Marten A, Renoth S, Heinicke T, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003;14:483-94.
45. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387-95.
46. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003;21:873-86.
47. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologie results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
48. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-9.
49. Svane IM, Soot ML, Buus S, Johnsen HE. Clinical application of dendritic cells in cancer vaccination therapy. APMIS 2003;111:818-34.
50. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996;184:1953-62.
51. Masten BJ, Olson GK, Kusewitt DF, Lipscomb MF. Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol 2004;172:4077-83.
52. McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking fits ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000;95:3489-97.
53. Parajuli P, Mosley RL, Pisarev V et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 2001;29:1185-93.
54. Shurin GV, Chatta GS, Tourkova IL, Zorina TD, Esche C, Shurin MR. Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Exp Gerontol 2004;39:339-48.
55. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol 2003;15:725-30.
56. Serot JM, Foliguet B, Bene MC, Faure GC. Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium. Neuroreport 1997;8:1995-8.
57. Jenks S. After initial setback, IL-12 regaining popularity. J Natl Cancer Inst 1996;88:576-7.
58. Mazzolini G, Qian C, Xie X, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999;6:514-22.
59. + T cells. Immunity 2005;22:371-83.
60. + B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother 2004;53:1135-45.
61. + T cell-mediated antigen-specific immune-therapy in a mouse model of cervical cancer. Cancer Res 2005;65:2018-25.